Ciclosporin ophthalmic - Santen SAS

Drug Profile

Ciclosporin ophthalmic - Santen SAS

Alternative Names: Ciclosporin - Santen SAS; Cyclokat; Ikervis; Nova 22007; Vekacia

Latest Information Update: 12 Jan 2017

Price : $50

At a glance

  • Originator Novagali Pharma
  • Developer Santen Pharmaceutical; Santen S.A.S.
  • Class Antineoplastics; Antipsoriatics; Antirheumatics; Ciclosporins; Eye disorder therapies; Neuroprotectants
  • Mechanism of Action Calcineurin inhibitors; Free radical inhibitors; Immunosuppressants; Mitochondrial permeability transition pore inhibitors; P-glycoprotein inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Allergic conjunctivitis
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity No

Highest Development Phases

  • Marketed Dry eyes
  • Phase III Allergic conjunctivitis

Most Recent Events

  • 23 Nov 2016 Launched for Dry eyes (In adults) in France (Ophthalmic) before November 2016
  • 04 Nov 2015 The UK's NICE issues final draft guidance recommending the use of ciclosporin for Dry eyes (In adults)
  • 04 Sep 2015 The Scottish Medicines Consortium accepts ciclosporin ophthalmic for Dry eyes (In adults) for use within the NHS Scotland
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top